A Study of LY3493269 in Participants With Type 2 Diabetes

NCT04515576 · Completed

Last updated 2026-05-28

This study tests the safety of the experimental drug LY3493269 in adults with type 2 diabetes.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, double-blind basic-science study

Participants 56 people

Who can join Ages 18–70 · all sexes

Timeline Started 2020-08 · est. completion 2021-03

Where 3 sites · United States

What this study is testing ClinicalTrials.gov NCT04515576 ↗

Description as written by the study sponsor.

The main purpose of this study is to determine the side effects related to LY3493269 in participants with type 2 diabetes. Blood tests will be performed to check concentrations of LY3493269 in the bloodstream. Each enrolled participant will receive LY3493269, dulaglutide, or placebo. The study will last up to approximately 16 weeks for each participant and may include up to 11 visits.

Treatments tested

LY3493269 Drug

Administered SC
Dulaglutide also known as LY2189265 Drug

Administered SC
Placebo Drug

Administered SC

Main thing measured	Number of Participants With One or More Treatment-Emergent Adverse Event(s) (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
Sponsor	Eli Lilly and Company
Conditions studied	Diabetes Mellitus, Type 2
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT04515576 ↗